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benefit to brachytherapy in a boost situation, and in retreating 
recurrent cancer where it may be necessary to restrict reirradiation of 
critical structures that received significant dose in the first 
treatment. 
Though permanent I125 seed implants have been successful in 
delivering low-dose-rate brachytherapy to prostate, most 
brachytherapy now uses high dose-rate plans from Ir192 which have 
the advantage that more precise dosing is obtained by modern remote 
afterloading systems which can vary dwell times at each position of 
the source. Radiobiologically, high dose-rate delivery is also 
advantageous in sparing late-reacting normal tissue where repair is 
usually slower than in the malignancy, though this biological 
advantage does require high dose-rate brachytherapy to be 
fractionated. 
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Introduction: In breast cancer, the target volume for a boost to the 
high risk area of residual disease is the primary tumour bed including 
the surrounding breast tissue. Especially in Europe, the use of 
brachytherapy (BT) as a boost modality is gradually being replaced by 
3D-CRT photon beam techniques because of logistic reasons. However, 
multi-catheter interstitial BT remains popular, especially for APBI, and 
is being investigated for treatment of recurrences/new primaries in 
the same breast.  
Technical aspects: Especially tumours located centrally or peripheral 
in the breast are suited for treatment with BT. Rigid or flexible 
afterloading catheters are placed under anaesthesia in the breast 
tissue around the lumpectomy cavity. The number of catheters 
depend on the size and shape of the target, in agreement with BT 
guidelines. Most often 5-9 catheters are positioned at 1-2 cm distance 
in 1-3 planes to ensure adequate coverage and a homogeneous dose. 
The lumpectomy cavity can be identified by pre-operative imaging, 
palpation, per-operative ultrasound or radio-opaque clips positioned 
during surgery. A template is used to properly position the catheters. 
A planning-CT scan for dosimetry is made the day after the 
implantation to allow resolution of swelling. The CTV is delineated as 
the lumpectomy cavity with a margin in all directions (often 1-1.5 cm) 
in the breast tissue, thereby excluding the skin (at least 5 mm) and 
pectoral muscles. Currently, a PDR (15-20 pulses of 1 Gy) or HDR (7 
Gy) 192Ir after-loader is mostly used. 3D-TPS dwell-time optimisation is 
used based on the CTV taking into account the implant geometry.   
Results: In the EORTC “boost-trial”1, a total of 2661 patients received 
a boost dose of 16 Gy after complete tumour resection. The boost 
technique was: 63% direct electron field, 28% photon beams and 9% 
interstitial BT. The 10-year cumulative incidence of local relapse was 
6.3% for electrons (95% CI. 5.1-7.5%), 5.3% for photons (95% C.I. 3.6-
7.0%) and 3.7% for BT (95% C.I. 1.2-6.2%) (p = 0.13). The occurrence of 
(any grade of) fibrosis was similar in the 3 groups: 70%, 66% and 72%, 
respectively. Harms2 treated 113 patients with risk factors for local 
control (close or positive margins, vascular invasion, T2G3) with an 
interstitial PDR boost of 15-25 pulses of 1 Gy.  At 5 years, the 
actuarial local recurrence-free survival rate was 95%.  Grade 3 skin or 
soft tissue toxicity developed in 10.8% of patients treated with a boost 
of  ≤20 Gy and 54.6% of patients treated with >20 Gy (p < 0.01).  
Cosmetic outcome was scored as excellent or good in 90% by patient 
assessment, and in 80% by physician assessment. Niehoff3 found no 
difference in the outcome between interstitial HDR or PDR BT in re-
irradiation for breast or chest wall recurrences of 32 patients.   
Advantages and challenges: As with BT the implant moves together 
with the lumpectomy cavity, no supplementary margin is required to 
obtain the PTV.  Moreover, the shape and size of the surgical cavity is 
less important as irregularly shaped cavities can be conformally 
treated using modern treatment planning techniques. Oncoplastic 
resection and reconstruction techniques offer a challenge for proper 
localisation of the CTV, with BT offering the advantage of the ability 
to shape the treated volume based on imaging and marker clips 
positioned around the primary tumour bed. As anaesthesia is required 
for the implant procedure, a challenge remains to either perform it 
under local anaesthesia or to per-operatively combine it with tumour 
resection. Delivering BT according to current standards requires 
specialised training and experience of a team consisting of radiation 
oncologists, medical physicists and radiation technologists.  
Conclusions: The brachytherapy technique has several advantages and 
therefore will continue to be used, especially for APBI. In addition, an 
appealing new feature lies in its use as secondary breast conserving 
treatment. 
1 Poortmans P et al. Radiother Oncol. 2004;72:25-33. 
2 Harms W et al. Strahlenther Onkol 2002;178:607-614. 
3 Niehoff P et al. Strahlenther Onkol 2006;182:102-107. 
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High-dose-rate (HDR) brachytherapy is an established curative 
treatment option for patients diagnosed with prostate cancer. Several 
advantages of HDR brachytherapy over other radiotherapy techniques 
have been identified: (1) the accurate positioning of the sources by 
first implanting non-active guide needles, (2) the possibility to exactly 
choose the position of the source over the entire length of every 
single needle, (3) the absence of any target movement during 
irradiation, (4) the possibility of “on line” adjustments of dwell source 
locations  according to 3D planning based on individual dose 
prescription, (5) the absence of any need for pre-implant needles 
preparation, and finally (6) a safer radio-protection profile as 
compared to permanent seeds implant procedure. 
The greatest clinical experience with HDR for prostate cancer involves 
its combination with EBRT. A systematic review of available literature 
has compared EBRT alone (at doses > 75 Gy), EBRT combined with 
HDR brachytherapy boost and EBRT combined with LDR permanent 
seeds boost in terms of efficacy endpoints. Despite the fact that 
patients treated with EBRT+HDR boost had more advanced disease, 
both biochemical disease free survival (biochemical Not Evidence of 
Disease, bNED) and overall survival rates were significantly better 
with this combination. Moreover the results of the only phase III 
randomized trial available in this field comparing EBRT alone (55 Gy in 
20 fractions) versus a combined EBRT (35,75 Gy in 13 fractions) + a 
HDR boost of 2 fractions of 8,5 Gy showed a significant advantage in 
bNED favoring the combined arm.  
Acute toxicity consists of mild LUTS (dysuria, urinary frequency, 
urgency) in 40 to 60% of patients but grade 3 genito-urinary (GU) 
symptoms are only presents in 1-5%. The return to base-line values is 
obtained much earlier than after LDR brachytherapy. In the 
immediate post-implant hours, hematuria is also relatively common 
but resolves rapidly . Urethral stricture is the most frequent non-
trivial late toxicity reported occurring in the bulbo-membranous 
urethra in more than 90% of the cases. Overall, it develops in 5 to 15% 
of patients with patient-related predictors being identified such as a 
prior history of TURP, an elevated pre-implant IPS-Score, older age, 
prostate volume (and use of neo-adjuvant ADT for pre-implant 
downsizing) and hypertension but also with a number of treatment-
related ones (HDR dose per fraction, number of midlines needles 
implanted, a long Z-axis of the CTV). Incontinence is less common and 
typically related to post-implant need of a TURP. Gastro-intestinal 
(GI) toxicity is frequently dependent on EBRT protocol adopted 
(irradiated volumes, prostate alone versus pelvis ± prostate CTV, 
dose/fraction to the pelvis) with grade 3 toxicity reported 
occasionally and proctitis, anal pain and rectal bleeding occurring in 
less than 5% of patients in all published papers.  
Several areas remain for further investigations and should be explored 
in future trials. (1) The optimal dosing regimens is still unclear: the 
first published series adopted  HDR schedules of two or more fractions 
while recently protocols proposing a single fraction/implant  have 
been developed with encouraging early results thus minimizing the 
risk of potential needles/catheters displacement between fractions. 
(2) HDR brachytherapy has been proposed for local salvage after 
biopsy proven intraprostatic relapse of irradiated prostate cancers 
with encouraging results but larger series with longer follow-up are 
needed to fully validate this strategy . (3) The typical inhomogeneous 
dose distribution obtained with brachytherapy techniques can be 
exploited in view of a “focal irradiation” of the prostate for carefully 
selected patients harboring limited unilateral cancers. (4) Costs of 
temporary HDR brachytherapy are limited. Rigorous cost-analysis and 
comparisons between therapeutic alternatives have so far never been 
attempted but if HDR brachytherapy techniques are able to 
convincingly demonstrate a cost-effective advantage as compared to 
other therapeutic options for localized prostate cancer, the procedure 
is likely to be offered in the near future to increasing numbers of 
patients.  
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Introduction: Primary radiotherapy in form of external beam 
radiotherapy (EBRT) combined withchemotherapy or combined with 
local dose escalation by brachytherapy enables anal sphincter 
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preservation and avoids permanent colostomy. Aim of this work was to 
give an overview on up-to-date technical possibilities and clinical 
results of the brachytherapy boost treatment in anal canal cancer.  
Material and Methods: A literature review was performed and 
synchronized with personal experience on the field. Special focus was 
taken on image guided (image adapted) interstitial brachytherapy 
methods. Investigated imaging guidance possibilities include the use 
of 3D transrectal ultrasound, MRI- and CT imaging. Preplanning and 
real-time planning methods are discussed. The role of FDG  -PET in 
target definition as well the role of LDR, PDR and HDR brachytherapy 
methods were analyzed in relation to clinical results. Outcome and 
toxicity data were reviewed according to different dose levels and 
techniques. 
Results: Modern external beam technology (IMRT) improves the results 
of radiotherapy w/o chemotherapy. FDG-PET seems to be superior to 
CT in visualization of the primary tumor. Image fusion (PET/MRI /CT) 
can improve the results of a single imaging method; however, 3D 
transrectal ultrasound represents the most appropriate local imaging 
for target definition. Radiation dose is associated with local control in 
locally advanced anal cancer: higher dose and shorter overall 
treatment time (>54 Gy within 60 days) improve the results. Most of 
the studies report local control (LC) rates with anal function 
preservation at five years of >80% in small tumors and ~ 65-70% in 
T3/4 disease. Nodal stage is the most significant factor influencing 
overall survival (~66% at 5 years). PDR appears to be able reproducing 
the good continuous LDR treatment results. Image guided/adapted 
HDR brachytherapy boost complementary to IMRT w/o chemotherapy 
results in moderate decrease of late radiation proctitis data. Usually, 
brachytherapy boost reduce severe acute toxicity of high-dose IMRT 
and offer a low late toxicity rate (18% G3/G4). Controlled QoL 
investigations showed slightly better but not significant differences in 
toxicity of HDR boost compared to IMRT boost - in advantage of 
brachytherapy.  
Conclusions: Interstitial brachytherapy boost complementary to 
external beam treatment is an effective dose escalation method in 
function preservation therapy of anal canal cancers. Total dose level 
and total treatment time are important factors for the outcome. 
Modern, image guided and adapted brachytherapy technology 
compared to careful patient selection has the potential to reduce late 
toxicity and preserve function.  
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Introduction: After a golden age (1980-1990) with a lot of 
publications and presentations of Head and Neck (H&N) cancers and 
LDR manual brachytherapy this area has become an increasing silent 
area of brachytherapy (BT). 
This happened despite of the following:  
 Good historical data with high local control rate (LC) and 
preservation of function and anatomy.  
 New emerging technologies (PDR and HDR) with perfect 
radiation protection and improved patient care  
 Improved 3D CT-based dose planning with possibilities for dose 
optimization.  
Materials and Results: Since 1994 PDR BT has been routinely used in 
our hospital as a modern substitute for LDR in the treatment of H&N 
cancers. We present our experience in four different indication groups 
with examples: 
A) Mono brachytherapy for cancer of the Lip (PDR 60Gy for 6 days) 
where we found a 5- year LC of 95 %. In other T1-T2 Squamous or 
Basal cell Carcinomas in the H&N region treated by interstitial or 
surface applications we found a 90% LC rate. 
B) Boost brachytherapy (PDR 35 Gy for 3,5 days) of Base of Tongue 
(BOT) cancer (43% were T3-T4) we obtained 89% LC after 5 years. A 
lot of other areas for BT boost in H&N cancers are also of interest. 
C) Reirradiation of local recurrences. No systematic data available. 
High LC reported but with a significant risk of soft tissue necroses. 
 D) Adjuvant brachytherapy after marginal or non-radical surgical 
resection. No systematic data available. The combined procedure is 
feasible in our experience and should be further investigated in the 
future.  
 
Discussion and conclusions:  In our experience modern machine 
afterloading with PDR is at least as effective as classical LDR BT. 
Systematic data on HDR BT in H&N cancers is sparse but probably is 
similar in effect. 
Modern BT will improve patient care and dose planning. 
Long time follow up with high patient numbers is crucial to study 
these relatively rare tumour sites. International pooled data analyses 
organized by the ESTRO H&N working group are being planned. 
Theoretical education (an ESTRO course) and practical training (at 
several European training sites organized by ESTRO) in modern H&N 
cancer brachytherapy are essential for the future development of this 
area. 
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The ULICE project - Union for Light Ion Centers in Europe - started in 
2009 and it is now in its final phase. In the ULICE community a 
discussion on how to go ahead exploiting the major scientific results 
got from the project research activities is open. The most important 
output will be the creation of a European Hadron Therapy Research 
Board. This structure will be a multi-centres research organisation 
willing to go beyond ULICE. Taking advantage of the network of 
communication and research, both clinical and pre-clinical, 
constructed during the course of the project, it should be feasible to 
continue with exchange of experiences, enhance clinical and 
translational research between current, and future, European Hadron 
Therapy Centers, all of them being partners of the ULICE consortium. 
Mentioned multi-centre international setting can really urge radio-
oncology and hadron therapy in particular to raise a shared clinical 
evidence.   
The main tasks of the building up European Hadron Therapy Research 
Board will be 1) to guide the design, implementation, operation and 
continuous evaluation of a prospective multi-centre database for 
patients treated in a defined consortium of centres with carbon ions, 
protons, advanced photons; 2) to guide the design, performance and 
results of database orientated research; 3) to design, to decide and to 
follow up on multi-centre phase I, II, and III clinical studies performed 
in the carbon-ion centres alone or in combination with photon and/or 
proton facilities; 4) to link translational research from various areas of 
interest and research groups to ongoing and projected clinical trial 
and database orientated research. 
The activities of this European Hadron Therapy Research Board will be 
linked to all relevant clinical radiotherapy research organisations and 
networks on the international/ national/regional level in European 
member states and regions which focus on hadron and advanced 
photon radiotherapy research.  
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MEDRAPET (MEDical RAdiationProtection Education and Training, 
MEDRAPET) is a European Commission project aimed to improve the 
implementation of the Medical Directive’s provisions related to 
radiation protection education and training of medical professionals in 
the EU member states. The professional organizations involved include 
the European Society of Radiology (ESR) as a coordinator, the 
European Federation of Organizations for Medical Physics (EFOMP), 
the European Federation of Radiographer Societies(EFRS), the 
